Status:
COMPLETED
AZD0530 Phase II Study in Patients With Advanced Ovarian Cancer
Lead Sponsor:
AstraZeneca
Conditions:
Ovarian Neoplasms
Ovarian Cancer
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
The main purpose of this study is to determine if AZD0530 can improve the efficacy of standard chemotherapy for the treatment of ovarian cancer
Eligibility Criteria
Inclusion
- Have a diagnosis of advanced ovarian cancer
- Have evidence of recurrence or disease progression at least 6 months following treatment cessation of 1st or 2nd line platinum containing therapy
- Estimated life expectancy of more than 12 weeks
Exclusion
- Central Nervous System (CNS) metastases
- Received more than 2 prior chemotherapy regimens for ovarian cancer treatment
- Inadequate bone marrow reserve
- Inadequate liver function, renal function or low haemoglobin
- Pregnant, breastfeeding or if of child-bearing status unwilling to use an acceptable method of contraception
Key Trial Info
Start Date :
April 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2012
Estimated Enrollment :
211 Patients enrolled
Trial Details
Trial ID
NCT00610714
Start Date
April 1 2008
End Date
January 1 2012
Last Update
December 18 2012
Active Locations (50)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Pleven, Bulgaria
2
Research Site
Plovdiv, Bulgaria
3
Research Site
Sofia, Bulgaria
4
Research Site
Varna, Bulgaria